What's on

  • November 27, 2014

    Art and science meet in the book Sketching científic IDIBAPS

    The art of urban natural drawing, or sketching, is a social and artistic phenomenon gaining adherents worldwide at great speed. The IDIBAPS has promoted over the past year, several activities to publicize the research that is carried out in the laboratories daily, through this artistic side. On November 20th, as part of Science Week in Catalonia, it was presented the final result of this project: the book Sketching científic IDIBAPS, the result of the two workshops in scientific sketching that have been carried out, one with professional Sketchers and the other, open to citizens.

    Read the rest of this entry

  • November 24, 2014

    The IDIBAPS organized a course to promote translational research in Diabetes

    The IDIBAPS hosted last week the course "Introduction to Research in Diabetes Mellitus", designed to promote awareness and interest about translational research for endocrinology in diabetes in senior residents and specialists in endocrinology. The course was organized by Dr. Anna Novials, who leads the IDIBAPS group Molecular and Metabolic Alterations in Diabetes and is the vice-president at the Spanish Diabetes Society (EDS), and consisted in theorical and practical classes about recent advances in biomedicine, metabolic study of patients and the basis of genetics and epigenetics of diabetes.

    Read the rest of this entry

  • November 13, 2014

    Researchers identify a key protein in pancreatic cancer development

    Researchers from the IDIBAPS and the University of Barcelona (UB) have described an interaction between the protein HNRNPA2B1 and pancreatic cancer development which remained unknown. The study, published in the journal Gastroenterology, has proved in human cancer cell lines that this protein is essential to the correct activity of the oncogenic protein KRAS, related to cancer start and development. The interaction between HNRNPA2B1 and the protein codified by the gene KRAS is a potential therapeutic target against pancreatic cancer, one of the tumours with a worse prognosis. The study was conducted by Neus Agell, professor at the Department of Cell Biology, Immunology and Neurosciences of the Faculty of Medicine of UB, who leads the Cellular compartments and signaling team at IDIBAPS. The first author of the study is Carles Barceló, PhD Student at the former UB Department.

    Read the rest of this entry

  • November 12, 2014

    A study shows that elite controllers have a similar genetic profile to that of HIV-uninfected people

    The elite controllers (EC) are those people in whom AIDS does not progress despite being infected with HIV. A study led by the IDIBAPS and published in the PLOS ONE journal focuses on whether these EC have a specific genetic profile, different from other patients with HIV, which allows them to control viremia without the need of antiretroviral therapy. Thus, researchers have identified 23 miRNAs differentially expressed, four of which are over-expressed in EC and people without the disease and another 19 are under-expressed in this population compared to patients with HIV. The study was led by Dr. Mireia Arnedo and Dr. Montserrat Plana, researchers at the IDIBAPS group of Infectious Diseases and AIDS, led by Dr. Josep Maria Gatell. The article’s first author is Dr. Lander Egaña-Gorroño.

    Read the rest of this entry

  • November 11, 2014

    An antiviral combination reaches 97% of effectiveness in liver transplant patients with hepatitis C

    In a study published in New England Journal of Medicine (NEJM), a combination of oral antiviral obtained a 97% curation rate for hepatitis C in a group of liver transplant patients in which eradication of infection was only possible in less than 50% of cases until now. Dr. Xavier Forns, Head of Hepatitis Unit at Hospital Clínic and researcher at IDIBAPS and at the Networked Biomedical Research Center in Hepatic and Digestive Diseases (CIBEREHD), leads this study in which his  group is the only European participant.

    Read the rest of this entry